Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Abstract Morbidity and mortality due to immunosuppression remain among the foremost clinical challenges in chronic lymphocytic leukemia (CLL). Although immunosuppression is considered to originate within the lymph node (LN) microenvironment, alterations in T and natural killer (NK) cells have almost exclusively been studied in peripheral blood (PB). Whereas chemoimmunotherapy further deteriorates immune function, novel targeted agents like the B-cell lymphoma 2 inhibitor venetoclax potentially spare nonmalignant lymphocytes; however, the effects of venetoclax on nonleukemic cells have not been explored. We address these unresolved issues using a comprehensive analysis of nonmalignant lymphocytes in paired LN and PB samples from untreated CLL patients, and by analyzing the effects of venetoclax-based treatment regimens on the immune system in PB samples from previously untreated and relapsed/refractory patients. CLL-derived LNs contained twice the amount of suppressive regulatory T cells (Tregs) and CLL supportive follicular T helper (Tfh) cells compared with PB. This was accompanied by a low frequency of cytotoxic lymphocytes. The expression of PD-1 by CD8+ T cells was significantly higher in LN compared with PB. Venetoclax-based treatment led to deep responses in the majority of patients, but also to decreased absolute numbers of B, T, and NK cells. Tfh cell, Treg, and PD-1+ CD8+ T cell numbers were reduced more than fivefold after venetoclax-based therapy, and overproduction of inflammatory cytokines was reduced. Furthermore, we observed restoration of NK cell function. These data support the notion that the immunosuppressive state in CLL is more prominent within the LN. Venetoclax-based regimens reduced the immunosuppressive footprint of CLL, suggesting immune recovery after the elimination of leukemic cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, venetoclax limits several features of CLL-associated immunosuppression in patients, including CTL exhaustion and NK-cell dysfunction (de Weerdt et al., 2019) and does not reduce the number of peripheral T cells in patients with HR + BCL2 + metastatic breast cancer (Lok et al., 2019).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as de Weerdt et al., 2019
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900 · cited 1×
“Venetoclax, an inhibitor of the antiapoptotic protein B-cell lymphoma 2 (Bcl-2), is highly effective in CLL, even as monotherapy.(28) High rates of minimal residual disease (MRD) negativity and low rates of progression are observed with venetoclax treatment in combination with anti-CD20 monoclonal antibodies, such as…”
BackgroundPorter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Seymour, J. F., Kipps, T. J., Eichhorst, B., Hillmen, P., D’Rozario, J., Assouline, S., Owen, C., Gerecitano, J., Robak, T., De la Serna, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713976 · Cited by 940
Self-citationThe who's who of T ‐cell differentiation: Human memory T ‐cell subsets
Mahnke, Y. D., Brodie, T. M., Sallusto, F., Roederer, M., & Lugli, E. (2013) · European Journal of Immunology · doi:10.1002/eji.201343751 · Cited by 817 · cited 1×
“effector memory T cells based on CD27 and CD45RA expression.(43) Although the differentiation status of CD4(1) T cells did not differ between LN and PB in CLL patients and HCs, the CD8(1) compartment in CLL patients consisted of a larger proportion of central memory T cells in the LN in comparison with the PB (37.”
ResultHerishanu, Y., Pérez-Galán, P., Liu, D., Biancotto, A., Pittaluga, S., Vire, B., Gibellini, F., Njuguna, N., Lee, E., Stennett, L., et al. (2011) · Blood · doi:10.1182/blood-2010-05-284984 · Cited by 815
Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-507947 · Cited by 810 · cited 1×
“Treatment with venetoclax-ibrutinib led to significantly reduced IL-4 production by CD4(1) T cells, in line with previous reports on abrogated TH2 cell responses after ibrutinib in vitro (Figure 6E).(26) We did not observe any clear changes in the cytokine-production profiles of CD8(1) T cells or Vd2 T cells after tre…”
ResultTam, C. S., O'Brien, S., Wierda, W., Kantarjian, H., Wen, S., Do, K.-A., Thomas, D. A., Cortes, J., Lerner, S., & Keating, M. J. (2008) · Blood · doi:10.1182/blood-2008-02-140582 · Cited by 693 · cited 2×
“6 months, leading to an extended period of increased infection risk.(20,21) Now that discontinuation of venetoclax-based treatments upon reaching deep remissions appears to be feasible,(29-31) it is of clinical relevance to assess whether lymphocyte counts recover after cessation, especially if the decrease in nonmali…”
BackgroundTurtle, C. J., Hay, K. A., Hanafi, L.-A., Li, D., Cherian, S., Chen, X., Wood, B., Lozanski, A., Byrd, J. C., Heimfeld, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.8519 · Cited by 662
Ramsay, A. G., Johnson, A. J., Lee, A. M., Gorgün, G., Le Dieu, R., Blum, W., Byrd, J. C., & Gribben, J. G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35017 · Cited by 600
Riches, J. C., Davies, J. K., McClanahan, F., Fatah, R., Iqbal, S., Agrawal, S., Ramsay, A. G., & Gribben, J. G. (2013) · Blood · doi:10.1182/blood-2012-09-457531 · Cited by 529 · cited 1×
“CD8(1) T cells from untreated CLL patients show increased production of effector-type cytokines.(16) Venetoclax-obinutuzumab treatment resulted in a significantly decreased production of IFN-g and a trend toward lower tumor necrosis factor-a production by CD8(1) T cells (Figure 4F).”
Background
Cited by
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
T follicular helper cells in cancer
Gutiérrez-Melo, N., & Baumjohann, D. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2022.12.007 · Cited by 209
Michels, K. R., Sheih, A., Hernández, S., Brandes, A., Parrilla, D., Irwin, B., Perez, A. M., Ting, H.-A., Nicolai, C. J., Gervascio, T., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006292 · Cited by 146
T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
Roessner, P. M., & Seiffert, M. (2020) · Leukemia · doi:10.1038/s41375-020-0873-2 · Cited by 144
Siddiqi, T., Soumerai, J. D., Dorritie, K. A., Stephens, D. M., Riedell, P. A., Arnason, J. E., Kipps, T. J., Gillenwater, H. H., Gong, L., Yang, L., et al. (2021) · Blood · doi:10.1182/blood.2021011895 · Cited by 127
Metadata
- Authors
- de Weerdt, I., Hofland, T., de Boer, R., Dobber, J. A., Dubois, J., van Nieuwenhuize, D., Mobasher, M., de Boer, F., Hoogendoorn, M., Velders, G. A., van der Klift, M., Remmerswaal, E. B. M., Bemelman, F. J., Niemann, C. U., Kersting, S., Levin, M.-D., Eldering, E., Tonino, S. H., & Kater, A. P.
- Affiliations
- Department of Hematology, Cancer Center Amsterdam, and
- Amsterdam University Medical Centers (NL)
- Cancer Center Amsterdam (NL)
- Genentech (US)
- Internal Medicine, Ikazia Hospital, Rotterdam, The Netherlands;
- Medisch Centrum Leeuwarden (NL)
- Ziekenhuis Gelderse Vallei (NL)
- Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands;
- Renal Transplant Unit, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;
- Copenhagen University Hospital (DK)
- Haga Hospital (NL)
- Albert Schweitzer Ziekenhuis (NL)
- Corresponding author
- Hofland, Tom
- Tonino, Sanne H.
- Kater, Arnon P.
- ORCID
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2019-09-10
- Volume
- 3
- Issue
- 17
- Pages
- 2642-2652
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- PMC
- PMC6737416
- OpenAlex
- W2973024487
- Cited by
- 110
- References
- 63
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 14 · 2023: 17 · 2022: 19 · 2021: 24 · 2020: 19
- FWCI
- 8.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Blood Advances (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Novo Nordisk Fonden (NNF16OC0019302)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- chronic lymphocytic leukemia, venetoclax, lymph node microenvironment, regulatory T cells, T follicular helper cells, PD-1, CD8+ T cells, natural killer cells, immunosuppression, BCL-2 inhibitor, inflammatory cytokines, immune recovery, relapsed/refractory CLL
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Blood, Female, Humans, Immune System, Immunosuppression Therapy, Killer Cells, Natural, Lymph Nodes, Lymphocytes, Male, Middle Aged, Sulfonamides, Leukemia, Lymphocytic, Chronic, B-Cell, CD8-Positive T-Lymphocytes, Bridged Bicyclo Compounds, Heterocyclic, T-Lymphocytes, Regulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. https://app.cochat.ai/papers/10.1182/bloodadvances.2019000360
- The paper
- de Weerdt, I., Hofland, T., de Boer, R., Dobber, J. A., Dubois, J., van Nieuwenhuize, D., Mobasher, M., de Boer, F., Hoogendoorn, M., Velders, G. A., van der Klift, M., Remmerswaal, E. B. M., Bemelman, F. J., Niemann, C. U., Kersting, S., Levin, M.-D., Eldering, E., Tonino, S. H., & Kater, A. P. (2019). Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. Blood Advances. https://doi.org/10.1182/bloodadvances.2019000360
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.